Literature DB >> 16323134

Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance.

Masao Ogata1, Hiroshi Kikuchi, Takako Satou, Rie Kawano, Junji Ikewaki, Kazuhiro Kohno, Kenji Kashima, Eiichi Ohtsuka, Jun-Ichi Kadota.   

Abstract

BACKGROUND: Human herpesvirus 6 (HHV-6) is increasingly recognized as an opportunistic and potentially life-threatening pathogen in recipients of allogeneic stem cell transplants (SCTs).
METHODS: To clarify the incidence and clinical relevance of active HHV-6 infection, serial titers of plasma HHV-6 DNA were determined for 50 allogeneic SCT recipients, using real-time polymerase chain reaction.
RESULTS: HHV-6 DNA was detected in plasma from 24 patients (48%). HHV-6 DNA was most frequently apparent approximately 14-27 days after transplantation. An increased risk of a positive result for HHV-6 DNA was associated with transplantation from an allelic-mismatch donor (P = .02) and administration of steroids (P = .04). Steroid use was associated with high HHV-6 DNA loads (P = .02). High HHV-6 DNA loads were correlated with delayed platelet engraftment (P = .04). Among patients who had positive results for HHV-6 DNA, the HHV-6 DNA load was higher in plasma from those who developed limbic encephalitis (n = 4) (P < .0001).
CONCLUSIONS: Active HHV-6 infection is not rare in SCT recipients. SCT from allelic-mismatch donors is associated with increased risk of active HHV-6 infection. Steroid therapy is associated with not only increased incidence of infection but also accelerated viral replication. Development of limbic encephalitis is associated with high HHV-6 DNA load.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16323134     DOI: 10.1086/498531

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

2.  Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study.

Authors:  Maheen Z Abidi; Parameswaran Hari; Min Chen; Soyoung Kim; Minoo Battiwala; Parastoo Bahrami Dahi; Miguel Angel Diaz; Robert Peter Gale; Siddhartha Ganguly; Usama Gergis; Jaime Green; Gerhard Hildebrandt; Joshua A Hill; Krishna Komanduri; Hillard Lazarus; David Marks; Taiga Nishihori; Richard Olsson; Sachiko Seo; Celalettin Ustun; Jean Yared; Dwight Yin; John Wingard; Baldeep Mona Wirk; Jeffrey Auletta; Caroline Lindemans; Marcie Riches
Journal:  Bone Marrow Transplant       Date:  2019-01-29       Impact factor: 5.483

3.  Diagnostic Clues to Human Herpesvirus 6 Encephalitis and Wernicke Encephalopathy After Pediatric Hematopoietic Cell Transplantation.

Authors:  Zsila Sadighi; Noah D Sabin; Randall Hayden; Elizabeth Stewart; Asha Pillai
Journal:  J Child Neurol       Date:  2015-01-06       Impact factor: 1.987

4.  Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay.

Authors:  Kaoru Wada; Naomi Kubota; Yoshinori Ito; Hiroshi Yagasaki; Koji Kato; Tetsushi Yoshikawa; Yasuyuki Ono; Hisami Ando; Yasuhiro Fujimoto; Tetsuya Kiuchi; Seiji Kojima; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

Review 5.  Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation.

Authors:  Masao Ogata; Naoyuki Uchida; Takahiro Fukuda; Kazuhiro Ikegame; Tomohiko Kamimura; Makoto Onizuka; Koji Kato; Hikaru Kobayashi; Yoji Sasahara; Masashi Sawa; Akihisa Sawada; Daiichiro Hasegawa; Masayoshi Masuko; Toshihiro Miyamoto; Shinichiro Okamoto
Journal:  Bone Marrow Transplant       Date:  2019-11-19       Impact factor: 5.483

6.  Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation.

Authors:  Hiroyuki Muranushi; Junya Kanda; Yasuyuki Arai; Takero Shindo; Masakatsu Hishizawa; Takashi Yamamoto; Tadakazu Kondo; Kohei Yamashita; Kazuo Matsubara; Akifumi Takaori-Kondo
Journal:  Br J Clin Pharmacol       Date:  2020-05-30       Impact factor: 4.335

7.  Clinical significance of cancer-related fatigue in multiple myeloma patients.

Authors:  Kazuhito Suzuki; Nobuyuki Kobayashi; Yoji Ogasawara; Takaki Shimada; Yuichi Yahagi; Katsuki Sugiyama; Shinobu Takahara; Takeshi Saito; Jiro Minami; Hiroki Yokoyama; Yutaro Kamiyama; Atsushi Katsube; Kazuhiro Kondo; Hiroyuki Yanagisawa; Keisuke Aiba; Shingo Yano
Journal:  Int J Hematol       Date:  2018-08-28       Impact factor: 2.490

8.  A case of pneumonitis and encephalitis associated with human herpesvirus 6 (HHV-6) infection after bone marrow transplantation.

Authors:  T Nakayama; F Okada; Y Ando; K Honda; M Ogata; K Goto; J Kadota; H Mori
Journal:  Br J Radiol       Date:  2010-12       Impact factor: 3.039

Review 9.  Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.

Authors:  M Ogata; T Fukuda; T Teshima
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

10.  Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.

Authors:  Amanda L Olson; Parastoo B Dahi; Junting Zheng; Sean M Devlin; Marissa Lubin; Anne Marie Gonzales; Sergio A Giralt; Miguel-Angel Perales; Esperanza B Papadopoulos; Doris M Ponce; James W Young; Nancy A Kernan; Andromachi Scaradavou; Richard J O'Reilly; Trudy N Small; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.